# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM 12b-25

### NOTIFICATION OF LATE FILING

						SEC File Number: CUSIP Number:	001-35621 379577208		
(Cl	heck one):	☑ Form 10-K ☐ Form N-SAR	☐ Form 20-F ☐ Form N-CSR	□ Form 11-K	□ Form 10-Q	□ Form 10	0-D		
		For Period Ended:  Transition Report of	n Form 20-F n Form 11-K n Form 10-Q n Form N-SAR						
Read Instruction (on back page) Before Preparing Form. Please Print or Type.  Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.  If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:									
	RT I — REGISTRAN								
	ll Name of Registrant								
For	rmer Name if Applicat	ble							
	60 General Armistead dress of Principal Exe	Avenue ecutive Office (Street and	Number)						
	dubon, PA 19403								
Cit	y, State and Zip Code								
PA	RT II — RULES 12b	-25(b) AND (c)							
	ne subject report coule completed. (Check bo		reasonable effort or expens	se and the registrant seek	ks relief pursuant to Ru	ule 12b-25(b), the fol	lowing should		
×	(b) The subject and thereof, will be	nual report, semi-annual refiled on or before the fift	il in Part III of this form co report, transition report on eenth calendar day follow on Form 10-D, or portion	Form 10-K, Form 20-F, ing the prescribed due d	Form 11-K, Form N-Selate; or the subject qua	AR or Form N-CSR, o arterly report or transi	tion report on		

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

#### PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

Globus Medical, Inc. (the "Company") concluded it is not able to compile all information necessary to complete its Form 10-K by March 1, 2017 without unreasonable effort or expense. The Company anticipates filing its Form 10-K for the fiscal year ended December 31, 2016 within the extension period.

#### PART IV — OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification							
	Daniel T. Scavilla	(610)	930-1800					
	(Name)	(Area Code)	(Telephone Number)					
(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).							
			¥ Yes □ No					
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?							
			☐ Yes ► No					
	If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.							
	GLOBUS MEDICAL, INC.							
	(Name of Registrant as Specifi	ed in Charter)						
has c	caused this notification to be signed on its behalf by the undersigned hereunto duly	authorized.						
Date	:: February 28, 2017 By:	/s/ Daniel T. Scavilla						
		Daniel T. Scavilla						
		Senior Vice President and Chie	f Financial Officer					
perso	RUCTION: The form may be signed by an executive officer of the registrant or by on signing the form shall be typed or printed beneath the signature. If the statement or than an executive officer), evidence of the representative's authority to sign on be	is signed on behalf of the registr	ant by an authorized representative					
	ATTENTION							

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).